All of DSpace

Browsing by Subject "minocycline"

Now showing items 1-4 of 4

    • Acinetobacter baumannii antibiotic resistance mechanisms 

      Kyriakidis I., Vasileiou E., Pana Z.D., Tragiannidis A. (2021)
      Acinetobacter baumannii is a Gram-negative ESKAPE microorganism that poses a threat to public health by causing severe and invasive (mostly nosocomial) infections linked with high mortality rates. During the last years, ...

    • Is minocycline a solution for multidrugresistant Acinetobacter baumannii? 

      Neonakis, I. K.; Spandidos, D. A.; Petinaki, E. (2014)
      Minocycline is an old, safe, second-line antimicrobial agent that has drawn attention over the last fewyears as a possible therapeutic option against multidrug-resistant Acinetobacter baumannii (MDRAB) clinical isolates. ...

    • Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study 

      Pournaras S., Dafopoulou K., Del Franco M., Zarkotou O., Dimitroulia E., Protonotariou E., Poulou A., Zarrilli R., Tsakris A., Skoura L., Themeli-Digalaki K., Perivolioti E., Tsiplakou S., Karavassilis V., Panopoulou M., Orfanidou M., Hadjichristodoulou C., Levidiotou S., Gikas A., Greek Study Group on Acinetobacter Antimicrobial Resistance (2017)
      In a previous nationwide study in Greece, OXA-58 was the sole carbapenemase present among carbapenem-resistant Acinetobacter baumannii (CRAB) isolated between 2000 and 2009. In this study, the antibiotic resistances, ...

    • Tetracyclines Diminish In Vitro IFN-γ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis 

      Florou D.T., Mavropoulos A., Dardiotis E., Tsimourtou V., Siokas V., Aloizou A.-M., Liaskos C., Tsigalou C., Katsiari C., Sakkas L.I., Hadjigeorgiou G., Bogdanos D.P. (2021)
      Introduction: Limited data from clinical trials in multiple sclerosis (MS) reported that minocycline, a widely used antibiotic belonging to the family of tetracyclines (TCs), exerts a beneficial short-lived clinical effect ...